<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?>

<feed xmlns="http://purl.org/atom/ns#" version="0.3" xml:lang="en-US">
<link href="https://www.blogger.com/atom/16491539" rel="service.post" title="Asbestosis Diagnosis Blog" type="application/atom+xml"/>
<link href="https://www.blogger.com/atom/16491539" rel="service.feed" title="Asbestosis Diagnosis Blog" type="application/atom+xml"/>
<title mode="escaped" type="text/html">Asbestosis Diagnosis Blog</title>
<tagline mode="escaped" type="text/html">A history of asbestos exposure may provide the first clue to an asbestosis diagnosis or a pleural mesothelioma diagnosis. It may take years between a persons exposure to asbestos and the appearance of early symptoms such as shortness of breath and chest pain.</tagline>
<link href="http://www.asbestosis-diagnosis.com/blog/" rel="alternate" title="Asbestosis Diagnosis Blog" type="text/html"/>
<id>tag:blogger.com,1999:blog-16491539</id>
<modified>2006-05-31T13:57:00Z</modified>
<generator url="http://www.blogger.com/" version="6.72">Blogger</generator>
<info mode="xml" type="text/html">
<div xmlns="http://www.w3.org/1999/xhtml">This is an Atom formatted XML site feed. It is intended to be viewed in a Newsreader or syndicated to another site. Please visit the <a href="http://help.blogger.com/bin/answer.py?answer=697">Blogger Help</a> for more info.</div>
</info>
<convertLineBreaks xmlns="http://www.blogger.com/atom/ns#">true</convertLineBreaks>
<entry xmlns="http://purl.org/atom/ns#">
<link href="https://www.blogger.com/atom/16491539/114908381970193116" rel="service.edit" title="Clinical Research Management Tools To Target Silver-level Compatibility" type="application/atom+xml"/>
<author>
<name>Mesotheloma Network</name>
</author>
<issued>2006-05-31T08:56:59-05:00</issued>
<modified>2006-05-31T13:56:59Z</modified>
<created>2006-05-31T13:56:59Z</created>
<link href="http://www.asbestosis-diagnosis.com/blog/2006/05/clinical-research-management-tools-to.html" rel="alternate" title="Clinical Research Management Tools To Target Silver-level Compatibility" type="text/html"/>
<id>tag:blogger.com,1999:blog-16491539.post-114908381970193116</id>
<title mode="escaped" type="text/html">Clinical Research Management Tools To Target Silver-level Compatibility</title>
<content mode="escaped" type="text/html" xml:base="http://www.asbestosis-diagnosis.com/blog/" xml:space="preserve">&lt;DIV&gt;&lt;FONT face=Arial size=2&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/DIV&gt; &lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;   &lt;DIV class=OutlookMessageHeader dir=ltr align=left&gt;&lt;B&gt;&lt;FONT face=Arial    size=2&gt;OpenClinicaTM Targets National Cancer Institutes caBIG Silver-level    Compatibility&lt;/FONT&gt;&lt;/B&gt;&lt;/DIV&gt;   &lt;P&gt;&lt;FONT face=Arial size=2&gt;Akaza Research announces that OpenClinica, will be    one of the first clinical research management tools to target silver-level    compatibility under the National Cancer Institutes Cancer Bioinformatics Grid    (caBIG) initiative.&lt;/FONT&gt;&lt;/P&gt;   &lt;P&gt;&lt;FONT face=Arial size=2&gt;CAMBRIDGE, MA (PRWEB) May 31, 2006 -- Akaza    Research is pleased to announce that its next release of OpenClinica,    codenamed Sterling, will be one of the first clinical research management    tools to target silver-level compatibility under the National Cancer    Institutes Cancer Bioinformatics Grid (caBIG) initiative. caBIG is a major    initiative of the National Cancer Institute to create a World Wide Web of    cancer research with the stated goal to eliminate death and suffering due to    cancer by the year 2015.&lt;BR&gt;&lt;BR&gt;This is a fantastic opportunity for    OpenClinica and for cancer research, said Cal Collins, Akaza Researchs    President. The cancer research community is already starting to reap the    benefits of the Cancer Bioinformatics Grid. Because caBIG has embraced    principles of open source and open standards, we can deliver our open source    clinical trials platform, OpenClinica, in a way that adds materially to this    value.&lt;BR&gt;&lt;BR&gt;OpenClinicas Senior Product Coordinator, Tom Hickerson, said,    The National Cancer Institute is on the forefront of using technology to    accelerate the progress of cancer research. With caBIG, the National Cancer    Institute has recognized the need for systems to become more interoperable in    order to deliver the productivity that modern science demands. OpenClinica    Sterling will provide the adaptability that such a task requires.    OpenClinica enables sponsors and investigators to manage clinical trials in    multi-site studies. It is this inherent flexibility of the system that enables    OpenClinica to evolve so rapidly and to be deployed effectively in an    integrated research environment, Mr. Hickerson added. &lt;BR&gt;&lt;BR&gt;The cancer    Biomedical Informatics Grid, or caBIG, is a voluntary network or grid    connecting individuals and institutions to enable the sharing of data and    tools, creating a World Wide Web of cancer research. The goal is to speed the    delivery of innovative approaches for the prevention and treatment of cancer.    The infrastructure and tools created by caBIG also have broad utility outside    the cancer community. caBIG is being developed under the leadership of the    National Cancer Institute's Center for Bioinformatics. Additional information    on caBIG compatibility may be found at &lt;/FONT&gt;&lt;A    href="https://cabig.nci.nih.gov/guidelines_documentation" target=_blank&gt;&lt;FONT    face=Arial    size=2&gt;https://cabig.nci.nih.gov/guidelines_documentation&lt;/FONT&gt;&lt;/A&gt;&lt;FONT    face=Arial size=2&gt;.&lt;BR&gt;&lt;BR&gt;Akaza Research, a leading provider of open source    clinical trial software, is headquartered in Cambridge, Massachusetts.    Supported by the National Institutes of Health (NIH), Akaza has developed and    commercialized OpenClinica, the preeminent open source clinical trial data    collection and management software platform. Akaza brings Open Source Software    solutions into the mainstream of the clinical research enterprise by making    high quality, standards-based systems accessible for private and public    research. Akaza Research provides support, training, and consulting services    to its customers worldwide. See www.akazaresearch.com.&lt;BR&gt;&lt;BR&gt;OpenClinica is    an open source web-based software platform that enables sponsors and    investigators to manage clinical research data in multi-site studies. It    facilitates protocol configuration, design of case report forms, electronic    data capture, and study/data management. OpenClinica supports HIPAA and 21 CFR    Part 11 guidelines and is designed as a strictly standards-based, extensible,    and modular platform. OpenClinica v1.0 was released in October 2005 under the    GNU Lesser General Public License (LGPL). See &lt;/FONT&gt;&lt;A    href="http://www.OpenClinica.org" target=_blank&gt;&lt;FONT face=Arial    size=2&gt;www.OpenClinica.org&lt;/FONT&gt;&lt;/A&gt;&lt;FONT face=Arial size=2&gt;. OpenClinica 2.0    is scheduled to be released to beta testers this    summer.&lt;BR&gt;&lt;BR&gt;###&lt;BR&gt;&lt;BR&gt;Press Contact: Steve Glines &lt;BR&gt;Company Name:    Industrial Myth &lt;BR&gt;Email: email protected from spam bots &lt;BR&gt;Phone:    978-952-6340 &lt;BR&gt;Website: &lt;/FONT&gt;&lt;A href="http://www.akazaresearch.com"    target=_blank&gt;&lt;FONT face=Arial size=2&gt;www.akazaresearch.com&lt;/FONT&gt;&lt;/A&gt;&lt;FONT    face=Arial size=2&gt; &lt;/FONT&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;</content>
<draft xmlns="http://purl.org/atom-blog/ns#">false</draft>
</entry>
</feed>

